Description
GTX pharmaceuticals presented the results of a phase2 clinical trial evaluating Ostarine (MK-2866) in patients with cancer induced muscle loss (also known as cancer cachexia) at the Endocrine Society Annual Meeting, held in Washington 2009. In this study 159 cancer patients with cell lung cancer, colorectal cancer, non-Hodgkins lymphoma, chronic lymphocytic leukemia or breast cancer were randomized. Participants received a placebo, 1mg or 3mg Ostarine daily for 16 weeks. Patients were allowed to receive standard chemotherapy during the trial. Ostarine treatment led to statistically significant increases in lean body mass (LBM) and improvement in muscle performance in both the 1mg and 3mg cohorts. The primary endpoint of LBM was measured by a dual energy x-ray absorptiometry (DEXA) scan.
Reviews
There are no reviews yet.